223 related articles for article (PubMed ID: 37365642)
1. Homology-independent targeted insertion (HITI) enables guided CAR knock-in and efficient clinical scale CAR-T cell manufacturing.
Balke-Want H; Keerthi V; Gkitsas N; Mancini AG; Kurgan GL; Fowler C; Xu P; Liu X; Asano K; Patel S; Fisher CJ; Brown AK; Tunuguntla RH; Patel S; Sotillo E; Mackall CL; Feldman SA
Mol Cancer; 2023 Jun; 22(1):100. PubMed ID: 37365642
[TBL] [Abstract][Full Text] [Related]
2. Production and characterization of virus-free, CRISPR-CAR T cells capable of inducing solid tumor regression.
Mueller KP; Piscopo NJ; Forsberg MH; Saraspe LA; Das A; Russell B; Smerchansky M; Cappabianca D; Shi L; Shankar K; Sarko L; Khajanchi N; La Vonne Denne N; Ramamurthy A; Ali A; Lazzarotto CR; Tsai SQ; Capitini CM; Saha K
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36382633
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological interventions enhance virus-free generation of
Kath J; Du W; Pruene A; Braun T; Thommandru B; Turk R; Sturgeon ML; Kurgan GL; Amini L; Stein M; Zittel T; Martini S; Ostendorf L; Wilhelm A; Akyüz L; Rehm A; Höpken UE; Pruß A; Künkele A; Jacobi AM; Volk HD; Schmueck-Henneresse M; Stripecke R; Reinke P; Wagner DL
Mol Ther Methods Clin Dev; 2022 Jun; 25():311-330. PubMed ID: 35573047
[TBL] [Abstract][Full Text] [Related]
4. CRISPR-Mediated Non-Viral Site-Specific Gene Integration and Expression in T Cells: Protocol and Application for T-Cell Therapy.
Odé Z; Condori J; Peterson N; Zhou S; Krenciute G
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32604839
[TBL] [Abstract][Full Text] [Related]
5. Combining different CRISPR nucleases for simultaneous knock-in and base editing prevents translocations in multiplex-edited CAR T cells.
Glaser V; Flugel C; Kath J; Du W; Drosdek V; Franke C; Stein M; Pruß A; Schmueck-Henneresse M; Volk HD; Reinke P; Wagner DL
Genome Biol; 2023 Apr; 24(1):89. PubMed ID: 37095570
[TBL] [Abstract][Full Text] [Related]
6. High-yield genome engineering in primary cells using a hybrid ssDNA repair template and small-molecule cocktails.
Shy BR; Vykunta VS; Ha A; Talbot A; Roth TL; Nguyen DN; Pfeifer WG; Chen YY; Blaeschke F; Shifrut E; Vedova S; Mamedov MR; Chung JJ; Li H; Yu R; Wu D; Wolf J; Martin TG; Castro CE; Ye L; Esensten JH; Eyquem J; Marson A
Nat Biotechnol; 2023 Apr; 41(4):521-531. PubMed ID: 36008610
[TBL] [Abstract][Full Text] [Related]
7. Engineering Tripartite Gene Editing Machinery for Highly Efficient Non-Viral Targeted Genome Integration.
Nam H; Xie K; Majumdar I; Yang S; Starzyk J; Lee D; Shan R; Li J; Wu H
Res Sq; 2023 Oct; ():. PubMed ID: 37961210
[TBL] [Abstract][Full Text] [Related]
8. High-efficiency of genetic modification using CRISPR/Cpf1 system for engineered CAR-T cell therapy.
Ding R; Chao CC; Gao Q
Methods Cell Biol; 2022; 167():1-14. PubMed ID: 35152989
[TBL] [Abstract][Full Text] [Related]
9. Targeted Delivery of Chimeric Antigen Receptor into T Cells via CRISPR-Mediated Homology-Directed Repair with a Dual-AAV6 Transduction System.
Moço PD; Farnós O; Sharon D; Kamen AA
Curr Issues Mol Biol; 2023 Sep; 45(10):7705-7720. PubMed ID: 37886930
[TBL] [Abstract][Full Text] [Related]
10. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing.
Dimitri A; Herbst F; Fraietta JA
Mol Cancer; 2022 Mar; 21(1):78. PubMed ID: 35303871
[TBL] [Abstract][Full Text] [Related]
11. CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia.
Hu Y; Zhou Y; Zhang M; Ge W; Li Y; Yang L; Wei G; Han L; Wang H; Yu S; Chen Y; Wang Y; He X; Zhang X; Gao M; Yang J; Li X; Ren J; Huang H
Clin Cancer Res; 2021 May; 27(10):2764-2772. PubMed ID: 33627493
[TBL] [Abstract][Full Text] [Related]
12. Transposase-CRISPR mediated targeted integration (TransCRISTI) in the human genome.
Rezazade Bazaz M; Ghahramani Seno MM; Dehghani H
Sci Rep; 2022 Mar; 12(1):3390. PubMed ID: 35232993
[TBL] [Abstract][Full Text] [Related]
13. Safe harbor-targeted CRISPR-Cas9 homology-independent targeted integration for multimodality reporter gene-based cell tracking.
Kelly JJ; Saee-Marand M; Nyström NN; Evans MM; Chen Y; Martinez FM; Hamilton AM; Ronald JA
Sci Adv; 2021 Jan; 7(4):. PubMed ID: 33523917
[TBL] [Abstract][Full Text] [Related]
14. Virus-free CRISPR knock-in of a chimeric antigen receptor into
Shankar K; Zingler-Hoslet I; Shi L; Katta V; Russell BE; Tsai SQ; Capitini CM; Saha K
bioRxiv; 2024 Feb; ():. PubMed ID: 38405747
[TBL] [Abstract][Full Text] [Related]
15. ssDNA is not superior to dsDNA as long HDR donors for CRISPR-mediated endogenous gene tagging in human diploid RPE1 and HCT116 cells.
Mabuchi A; Hata S; Genova M; Tei C; Ito KK; Hirota M; Komori T; Fukuyama M; Chinen T; Toyoda A; Kitagawa D
BMC Genomics; 2023 May; 24(1):289. PubMed ID: 37248464
[TBL] [Abstract][Full Text] [Related]
16. Self-Cutting and Integrating CRISPR Plasmids Enable Targeted Genomic Integration of Genetic Payloads for Rapid Cell Engineering.
Bloemberg D; Sosa-Miranda CD; Nguyen T; Weeratna RD; McComb S
CRISPR J; 2021 Feb; 4(1):104-119. PubMed ID: 33616439
[TBL] [Abstract][Full Text] [Related]
17. Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sources.
Schmidts A; Marsh LC; Srivastava AA; Bouffard AA; Boroughs AC; Scarfò I; Larson RC; Bedoya F; Choi BD; Frigault MJ; Bailey SR; Leick MB; Vatsa S; Kann MC; Prew MS; Kleinstiver BP; Joung JK; Maus MV
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32900862
[TBL] [Abstract][Full Text] [Related]
18. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
[TBL] [Abstract][Full Text] [Related]
19. CRISPR/Cas9-mediated homology-directed repair by ssODNs in zebrafish induces complex mutational patterns resulting from genomic integration of repair-template fragments.
Boel A; De Saffel H; Steyaert W; Callewaert B; De Paepe A; Coucke PJ; Willaert A
Dis Model Mech; 2018 Oct; 11(10):. PubMed ID: 30355591
[TBL] [Abstract][Full Text] [Related]
20. Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells.
Stroncek DF; Lee DW; Ren J; Sabatino M; Highfill S; Khuu H; Shah NN; Kaplan RN; Fry TJ; Mackall CL
J Transl Med; 2017 Mar; 15(1):59. PubMed ID: 28298232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
